Contribution of mutations in ATM to breast cancer development in the Czech population
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
18497957
Knihovny.cz E-zdroje
- MeSH
- alternativní sestřih MeSH
- ATM protein MeSH
- DNA vazebné proteiny genetika metabolismus MeSH
- dospělí MeSH
- genetická predispozice k nemoci * MeSH
- heterozygot MeSH
- imunoenzymatické techniky MeSH
- lidé středního věku MeSH
- lidé MeSH
- metylace DNA MeSH
- mutace genetika MeSH
- mutační analýza DNA MeSH
- nádorové supresorové proteiny genetika metabolismus MeSH
- nádory prsu epidemiologie genetika patologie MeSH
- promotorové oblasti (genetika) genetika MeSH
- protein-serin-threoninkinasy genetika metabolismus MeSH
- proteiny buněčného cyklu genetika metabolismus MeSH
- věk při počátku nemoci MeSH
- ztráta heterozygozity MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Československo epidemiologie MeSH
- Názvy látek
- ATM protein, human MeSH Prohlížeč
- ATM protein MeSH
- DNA vazebné proteiny MeSH
- nádorové supresorové proteiny MeSH
- protein-serin-threoninkinasy MeSH
- proteiny buněčného cyklu MeSH
Mutations in the ATM gene are the cause of a rare autosomal recessive syndrome, ataxia-telangiectasia (AT). Of the general population, approximately 0.35-1% has been estimated to be heterozygous for a germline mutation in the ATM gene. The finding that ATM heterozygotes have an increased breast cancer risk was supported by some studies but not confirmed by others. In our study, the entire coding sequence of the ATM gene was prescreened for mutations by the protein truncation test to detect the chain-terminating mutations that are highly predominant in patients with AT. DNA sequencing then characterized 3 (1.9%) pathogenic mutations among 161 high-risk breast cancer patients. The c.5177+1G>A splicing mutation was a novel gene alteration. No mutation was detected in a group of 183 control individuals. Our results suggest that truncating mutations in ATM increase breast cancer risk and contribute to inherited breast cancer. The analysis further uncovered the c.1066-6T>G splicing mutation once among high-risk patients (0.6%) and twice among controls (1.1%) suggesting that this mutation does not confer an increase in breast cancer risk. On the other hand, individuals heterozygous for this truncating variant displayed loss of exon 11 in approximately 50% of ATM transcripts. Immunohistochemistry did not detect the ATM protein in the tumor sample carrying this mutation. Thus, the association of the c.1066-6T>G mutation with familial breast cancer remains uncertain. Loss of the wild-type ATM allele has not been detected in the tumor samples from heterozygous carriers of the ATM mutation. Our experiments did not detect the hypermethylation of the ATM promoter in any of the DNA samples from tumor tissues.
Germline mutation in the TP53 gene in uveal melanoma
Characterisation of ATM mutations in Slavic Ataxia telangiectasia patients